Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition.
Animals
Anti-Inflammatory Agents
/ pharmacology
Antineoplastic Agents
/ pharmacology
Antioxidants
/ pharmacology
Cardiotonic Agents
/ pharmacology
Cell Line, Tumor
Cell Survival
/ drug effects
Humans
Hypoglycemic Agents
/ pharmacology
Immediate-Early Proteins
/ antagonists & inhibitors
Molecular Targeted Therapy
Neuroprotective Agents
/ pharmacology
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Resveratrol
/ pharmacology
Docking
HCC
Homology modeling
Multi-target
Resveratrol
SGK1
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Dec 2019
01 Dec 2019
Historique:
received:
27
06
2019
revised:
30
08
2019
accepted:
02
09
2019
pubmed:
21
9
2019
medline:
15
1
2020
entrez:
21
9
2019
Statut:
ppublish
Résumé
Resveratrol (trans-3,4',5-trihydroxystilbene) is a polyphenolic natural product with a well-known polypharmacological profile that places it among the multi-target-directed ligands (MTDLs). Given its protective action against a wide number of chronic diseases, in this review, we introduce a general overview about the cardioprotective and antioxidant effects, the antidiabetic, neuroprotective and anti-inflammatory effects of this polyphenol. In the second part of the manuscript, we focused our attention on the anticancer activity of Resveratrol, given the alteration of many different signaling pathways, leading to suppression of tumor cell proliferation in numerous cancer types. Among the several anticancer targets involved in the mechanism of action of Resveratrol, here we introduce experimental and molecular modeling studies performed against the SGK1 protein as a novel anticancer target of Resveratrol. SGK1 inhibitors have been demonstrated to inhibit cell growth of different cancer cells. We demonstrated that resveratrol inhibits SGK1 in vitro and in intact cells, affecting proliferation and survival of HUH7 human hepatoma cells. Our findings demonstrate that resveratrol may function as a SGK1 inhibitor, suggesting possible applications in sodium retention and cancer.
Identifiants
pubmed: 31539779
pii: S0223-5234(19)30819-0
doi: 10.1016/j.ejmech.2019.111675
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antineoplastic Agents
0
Antioxidants
0
Cardiotonic Agents
0
Hypoglycemic Agents
0
Immediate-Early Proteins
0
Neuroprotective Agents
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
serum-glucocorticoid regulated kinase
EC 2.7.11.1
Resveratrol
Q369O8926L
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111675Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.